Blog

Because of the burgeoning interest surrounding fungi and all their amazing properties, “magic” mushrooms are no longer relegated to the fringe—and TRĒHouse magical mushrooms are leading the pack. And for those seeking a legit TreHouse magic mushrooms review, this is the place.

TRĒHouse is an up-and-coming brand obsessed with the benefits of functional mushrooms. Its magical mushroom line features its own proprietary blend of fungi and nootropics, which has the internet talking. If you’re curious about these popular compounds, consult with your primary physician before giving them a go.

Summary of the Best TRĒHouse Magic Mushroom Products

TRĒHouse is a Los Angeles-based purveyor of magically crafted (and legal) products that benefit the body, mind, and perhaps spirit (depending on who you talk to).

The brand is best known for proprietary blends of CBD and other cannabinoids, mushroom gummies and extracts, and more, with killer flavor combinations that make wellness fun.

TRĒHouse maintains some of the most stringent testing practices in the business, meaning you’ll be able to find a third-party COA for every product they sell.

FYI, TRĒHouse’s magic mushroom products produce psychotropic effects, but they do not contain psilocybin nor amanita muscaria (the mind-bending compounds in a traditional magic mushroom). Instead, they contain a bioavailable and efficacious blend of legal euphoric herbs, adaptogens, and amino acids meant to elicit a chilled-out state of bliss. 

Still, any person trying Tre House products should always start low and go slow, and it’s essential that you consult a doctor prior to starting your regimen.

Continue Reading: Green State

Psilocybin may boost resilience to stress

For this study — which was led by Kat Kiilerich, a doctoral researcher at the University of Southern Denmark — the researchers gave rats microdoses of psilocybin for 21 days.

After that time period, researchers discovered the rats tolerated the repeated microdoses of psilocybin well. They also did not show any signs of reduced pleasure, anxiety, or altered locomotor activity, which involves movement from one location to another.

Dr. Mikael Palner, associate professor, and head of the preclinical imaging core facility in the Research Unit for Clinical Physiology and Nuclear Medicine at the University of Southern Denmark, last author of this study, explained that the research team opted for microdoses of psilocybin because higher doses were likely to have the opposite effect, and to worsen mental health symptoms.

“It’s been shown that high doses [do] all of this, and that these [ill] effects mimic schizophrenia phenotypes [traits],” he told Medical News Today.

“Animals who are dosed with high chronic doses of LSD have even been used as models of schizophrenia. So yes, we were a bit happy that this was not the case for chronic low doses of psilocybin,” he said.

The scientists found that the repeated microdosing of psilocybin increased the rats’ stress resiliency, and they displayed fewer compulsive behaviorsTrusted Source.

“From RedditTrusted Source and other forums, we knew that people microdosed for obsessive-compulsive disorder (OCD), so the reduction in compulsive behaviors was our working hypothesis all the way,” Dr. Palner explained.

“It wasn’t until peer review that a clever reviewer assisted in redesigning the sucrose preference test, we had previously done that we noticed the resilience to stress. Compulsive actions and stress are tightly linked, and many psychiatric diseases are also worse in periods of high stress,” he added.

Continue Reading: Medical News Today

Psychedelics have entered the mainstream in a big way: Investors have staked billions on potential medical treatments, scientific research has skyrocketed and public sentiment signals growing acceptance.

And yet the major sources of data on drug use have big gaps when it comes to psychedelics, making it hard to gauge exactly how consumption is changing and in what ways.

Two reports out this week offer some much-needed data points on the public’s psychoactive preferences. Together, they suggest that psilocybin-containing mushrooms are now the most popular choice. And many people are opting to microdose, consuming a fraction of the usual dose, rather than taking a full trip.

“We’ve known that microdosing has become a cultural phenomenon, but all the surveys on drug use don’t ask about dosing,” says Eric Leas, an epidemiologist at the University of California, San Diego, whose research was published on Friday in JAMA Health Forum.

That study tracked internet search history on microdosing – a proxy for public interest – finding about a 1,250% increase since 2015. And searches for psilocybin started to outpace LSD in 2019.

Meanwhile, a separate report from the non-partisan RAND Corporation estimates that about 3% of the American public – approximately 8 million adults – have used psilocybin in the past year, making it the most popular hallucinogen in 2023.

The fact that psilocybin use eclipsed other popular psychedelics came as a “surprise” to Beau Kilmer, who co-directs the RAND Drug Policy Research Center and was the lead author of the study, which was published this week.

The runner-up was MDMA, or ecstasy, at just over 1%, followed closely by LSD. The report was based on a nationally representative survey of about 4,000 people and explores the policy implications of changing attitudes around psychedelics.

The impact of decriminalization on microdosing
Nearly half of those who tried psilocybin in the past year said they had elected to microdose, a trend that has caught on in many circles, including tech workers and suburban moms.
Source: NPR

Study found that the rate of microdosing-related Google searches grew by 1250% from 2015 to 2023, with over three million searches in 2023 alone. This surge in interest correlates with recent legislative changes decriminalizing or authorizing the use of psychedelic substances in therapy and permitting recreational cannabis use. The research fills a gap in understanding how policy changes affect substance use patterns.

Microdosing involves taking “sub-perceptual” doses of psychedelics, often over prolonged periods, with users claiming it improves cognition, mood and overall health without causing the intense hallucinogenic effects of higher doses. Despite the lack of clinical evidence supporting these health claims, interest in the practice appears to have grown over the past decade. Current survey data on microdosing are inadequate, prompting the study’s authors to analyze Google search behaviors as a proxy for public interest and to understand how policy reforms have influenced this interest.

The study period coincided with significant policy reforms on substance use. In 2012, Colorado became the first U.S. state to permit recreational cannabis use, and by 2023, 24 states had followed suit, encompassing half of the U.S. adult population. Additionally, eight states had cities or counties decriminalize psychedelic use, and two states legalized psychedelic-assisted therapy and decriminalized psychedelics statewide.

Using a dynamic event-time difference-in-difference model, the researchers assessed the causal effects of these policy changes. They used the year before a policy enactment as the reference and states that never adopted the policy as controls. Separate analyses for cannabis and psychedelic policies measured microdosing searches per 10 million Google queries, examining annual and monthly changes in search rates across the U.S.

The results showed that policies reducing criminal penalties for psychedelic and cannabis use were associated with increased interest in microdosing, with the largest increases occurring in states with the most permissive policies, such as Oregon and Colorado. By 2023, these policy reforms accounted for over a quarter of the differences in monthly microdosing search rates across states.

The study also examined trends in terms related to microdosing, such as substances commonly used for microdosing. Between 2015 and 2018, LSD was the top term related to the microdosing, while from 2019 to 2023, mushrooms were most frequently searched. Other terms included Adderall, cannabis, CBD, DMT, ketamine, and MDMA.

The researchers believe these findings reflect a growing societal interest in psychedelics and psychotropic substances as alternative therapies, possibly replacing evidence-based care. On a federal level, President Biden suggested reclassifying marijuana as a less dangerous drug in 2022, and the Justice Department approved this recommendation in May 2024. Kevin Yang, M.D., lead author of the study and a psychiatry resident at UC San Diego School of Medicine, believes these actions, along with state and local legislation, indicate a more open attitude toward psychotropics, potentially encouraging scientific investigation.

Yang emphasized the importance of rigorous research, stating, “As public interest in using psychedelics and cannabis for health grows, it’s crucial that the medical community conducts studies to establish a strong evidence base for their safety and efficacy. Without understanding the risks and benefits, people may turn to unproven alternative therapies, exposing themselves to potential dangers. It’s our responsibility as a medical community to ensure patients have access to safe, effective and evidence-based treatments.”

The authors expressed concern about the market for microdosed products. “Psilocybin and nearly all commonly microdosed substances are Schedule 1 controlled substances. Using these substances poses legal risks for consumers and concerns of product impurity because of a lack of manufacturing standards,” said Eric Leas, Ph.D., M.P.H., assistant professor in the UC San Diego Herbert Wertheim School of Public Health and Human Longevity Science and senior author of the paper. He noted that products claiming to be “magic mushrooms” for microdosing might not disclose ingredients or could contain harmful substances like Amanita muscaria, which lacks clinical support as a therapy and can be toxic.
Source: TODAY UCSD